

Covered for your **TRICARE**[®] patients

- Rayaldee[®] is available for a \$68 copay for up to a 90-day supply via **TRICARE[®] Pharmacy Home Delivery**
- Rayaldee[®] is available for a \$68 copay for up to a 30-day supply via **TRICARE[®] retail network pharmacy**
- Active Duty Service Members have no prescription drug cost (\$0) when using a military pharmacy, TRICARE[®] Pharmacy Home Delivery, or a TRICARE[®] retail network pharmacy for covered drugs

*Rayaldee is available for a \$34 copay for up to a 90-day supply via TRICARE Pharmacy Home Delivery if Rayaldee is determined to be medically necessary. The prescriber must complete, sign and submit the [TRICARE Pharmacy Program Medical Necessity Form for Vitamin D Analogs: Calcifediol \(Rayaldee\)](#).

Download a PDF of the Medical Necessity Form at <https://rayaldee.com/wp-content/themes/rayaldee/pdfs/hcp/tricare-rayaldee-letter-of-medical-necessity.pdf> or scan the QR code at the right to download.

Source: TRICARE[®] Costs and Fees 2022. <https://www.tricare.mil/publications>. <https://www.express-scripts.com/frontend/open-enrollment/tricare/fst/#/formularyPricing/home> / Date accessed: July 2022.

SCAN CODE



Call **OPKO CONNECT** at **1-844-414-OPKO** to speak with a Rayaldee[®]
Support Specialist Monday-Friday from 8 am to 8 pm ET or email
OPKOCONNECT@RXALLCARE.COM.

Indication and Limitations of Use

Rayaldee[®] (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

Important Safety Information

- **Hypercalcemia:** Excessive administration of vitamin D compounds, including Rayaldee, can cause hypercalcemia and hypercalciuria. Severe hypercalcemia due to substantial overdosage of vitamin D and its metabolites may require emergency attention. Patients should be informed about the symptoms of elevated calcium.
- **Digitalis toxicity:** Potentiated by hypercalcemia of any cause. Monitor serum calcium and signs and symptoms of digitalis toxicity more frequently when initiating or adjusting the dose of Rayaldee.
- **Adynamic Bone Disease:** Monitor for abnormally low levels of intact parathyroid hormone (iPTH) levels when using Rayaldee, and adjust dose if needed.
- The most common adverse reactions ($\geq 3\%$ and more frequent than placebo) were anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation.
- Care should be taken while dosing Rayaldee with cytochrome P450 inhibitors, thiazides, cholestyramine or drugs stimulating microsomal hydroxylation due to the potential for drug interactions.
- Serum calcium should be below 9.8 mg/dL before initiating treatment.
- Monitor serum calcium, phosphorus, 25-hydroxyvitamin D and iPTH 3 months after starting therapy or changing dose.

For Full Prescribing Information, visit **www.Royaldee.com**.